Get the Stockscreener App
0.59
3.04%
-0.0185
VBI Vaccines Inc. stock is currently priced at $0.59, with a 24-hour trading volume of 130.14K.
It has seen a -3.04% decreased in the last 24 hours and a +2.57% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.603 pivot point. If it approaches the $0.5861 support level, significant changes may occur.
Previous Close:
$0.6085
Open:
$0.5936
24h Volume:
130.14K
Market Cap:
$16.78M
Revenue:
$8.12M
Net Income/Loss:
$-113.96M
P/E Ratio:
-0.0428
EPS:
-13.7968
Net Cash Flow:
$-70.02M
1W Performance:
-3.12%
1M Performance:
+2.57%
6M Performance:
+16.88%
1Y Performance:
-79.58%
1D Range:
$0.5802
$0.61
52W Range:
$0.45
$3.47
VBI Vaccines Inc. Stock (VBIV) Company Profile
Name
VBI Vaccines Inc.
Sector
Industry
Phone
617-830-3031
Address
222 Third Street, Suite 2241, Cambridge, MA
VBI Vaccines Inc. Stock (VBIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-22 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Feb-25-21 | Initiated | Jefferies | Buy |
| Aug-27-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-16-19 | Initiated | Oppenheimer | Outperform |
| Nov-01-17 | Initiated | Canaccord Genuity | Buy |
| Oct-10-16 | Initiated | Laidlaw | Buy |
| Jul-26-16 | Initiated | Ladenburg Thalmann | Buy |
| May-07-15 | Initiated | Noble Financial | Buy |
View All
VBI Vaccines Inc. Stock (VBIV) Latest News
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Faraday Future Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Benzinga
VBI Vaccines Inc. Stock (VBIV) Financials Data
VBI Vaccines Inc. (VBIV) Revenue 2024
VBIV reported a revenue (TTM) of $8.12 million for the quarter ending September 30, 2023, a +833.56% rise year-over-year.
VBI Vaccines Inc. (VBIV) Net Income 2024
VBIV net income (TTM) was -$113.96 million for the quarter ending September 30, 2023, a -2.72% decrease year-over-year.
VBI Vaccines Inc. (VBIV) Cash Flow 2024
VBIV recorded a free cash flow (TTM) of -$70.02 million for the quarter ending September 30, 2023, a +8.67% increase year-over-year.
VBI Vaccines Inc. (VBIV) Earnings per Share 2024
VBIV earnings per share (TTM) was -$11.90 for the quarter ending September 30, 2023, a +7.11% growth year-over-year.
About VBI Vaccines Inc.
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.
3.69%
0.93%
Cap:
|
Volume (24h):